Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended September 30, 2016 (the company’s fiscal second quarter). The unaudited statements are consolidated. Vistagen is a clinical-stage biopharmaceutical company with no commercial products or sustainable revenue.
Business context and outlook
The company’s lead candidate, oral AV-101, is in Phase 2 development for major depressive disorder (MDD). The NIMH-funded Phase 2a study in treatment-resistant MDD was underway; Vistagen expected topline results in Q2 2017. The company anticipated starting its company-led Phase 2b adjunctive MDD study in the first half of 2017 and reporting topline results in Q3 2018. Vistagen also described early-stage drug-rescue and regenerative-medicine opportunities using its stem-cell technology platform.
Key financial metrics
| Metric | Three months ended September 30, 2016 | Six months ended September 30, 2016 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $1.606 million | $2.432 million |
| General and administrative expense | $1.494 million | $2.631 million |
| Total operating expenses / operating loss | $3.100 million | $5.063 million |
| Net loss | $3.101 million | $5.068 million |
| Net loss attributable to common stockholders | $3.342 million | $5.960 million |
| Loss per share attributable to common stockholders, basic and diluted | $0.42 | $0.91 |
Margins: Not meaningful because the company reported no revenue. Six-month operating cash use was $3.873 million; investing cash use was $7,700; financing provided $9.709 million. Cash increased by $5.829 million to $6.257 million.
Liquidity and liabilities at September 30, 2016: Current assets were $6.906 million and current liabilities were $1.797 million. Total assets were $7.023 million, total liabilities $2.936 million, and stockholders’ equity $4.087 million. Notes payable totaled $71,100, all current; capital lease obligations were $600. Accrued Series B preferred dividends were $1.102 million.
Changes versus comparable periods
- For the quarter, operating expenses fell 42% from $5.387 million in 2015, and net loss narrowed from $7.048 million. Lower G&A—especially reduced noncash stock-based compensation—was the main driver; R&D was modestly lower.
- For the six months, operating expenses declined to $5.063 million from $7.208 million, while R&D increased about 20% as AV-101 development advanced. G&A decreased from $5.179 million to $2.631 million, mainly reflecting lower noncash stock-based compensation and professional-services costs.
- Six-month net loss improved substantially from $36.572 million in 2015, largely because the prior-year period included a $26.700 million noncash loss on extinguishment of debt and a $1.895 million noncash warrant-liability change. The prior-year comparison also included greater interest expense.
- Operating cash use increased from $2.330 million in the prior-year six-month period to $3.873 million. Financing cash inflows rose primarily due to the May 2016 public offering.
Financing, risks, and unusual items
- The May 2016 public offering raised approximately $9.5 million net from common shares and warrants; the company also received $278,000 from Series B preferred units. The offering accompanied an uplisting to the NASDAQ Capital Market.
- Vistagen estimated its available resources would fund expected operations through the first half of 2017, including preparation for and launch of Phase 2b, but said funds were insufficient to complete that study. It estimated that at least $12 million more would be needed over the following 24 months to complete Phase 2b and fund operations through the second half of 2018. Additional financing was not assured and could dilute stockholders or be unavailable on acceptable terms.
- The company reported recurring losses, negative operating cash flows, and an accumulated deficit of $136.8 million. It warned that failure to obtain timely financing could require reductions or deferrals in research and development and could threaten its ability to continue as a going concern.
- Key development risks include uncertain Phase 2 results, regulatory requirements and timing, dependence on third-party clinical and manufacturing providers, competition, and limited intellectual-property protection. The filing states that Vistagen had no issued patents covering AV-101.
- Subsequent events included an October warrant exchange for common shares, November option grants for 560,000 shares, and a headquarters lease extension through July 2022. The company reported no legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Progress, enrollment, safety findings, and timing of topline results for the NIMH-funded Phase 2a study and the planned Phase 2b study.
- Whether the company can raise the additional capital it estimated is needed, and the financing terms, dilution, and resulting runway.
- Actual AV-101 development costs, including the anticipated material increase in spending during Phase 2b.
- Outstanding share count and potential dilution from preferred-stock conversions, warrants, options, and equity issued for services. The cover reports 8,379,921 common shares outstanding as of November 11, 2016.
- Patent application status and the scope and durability of intellectual-property protection for AV-101.